- Home
- VNDA
as 11-06-2025 3:55pm EST
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 249.4M | IPO Year: | 2006 |
| Target Price: | $14.00 | AVG Volume (30 days): | 682.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $5.70 | Next Earning Date: | 10-29-2025 |
| Revenue: | $212,074,000 | Revenue Growth: | 11.12% |
| Revenue Growth (this year): | 14.32% | Revenue Growth (next year): | 37.05% |
Latest Vanda Pharmaceuticals Inc. News
VNDA Breaking Stock News: Dive into VNDA Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
The Fly
2 days ago
Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls
MT Newswires
2 days ago
B. Riley Initiates Coverage on Vanda Pharmaceuticals With Buy Rating, $11 Price Target
Simply Wall St.
3 days ago
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St.
5 days ago
Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones
Simply Wall St.
7 days ago
High Growth Tech Stocks In US With Promising Potential
Simply Wall St.
7 days ago
High Growth Tech Stocks In The US Market With Promising Potential
Simply Wall St.
7 days ago
Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings
Compare VNDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNDA Vanda Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.